- Conditions
- Polycystic Ovary Syndrome
- Interventions
- Not listed
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 20 Years to 40 Years · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1801–1824
of 2,464
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HER2-Negative Metastatic Breast Cancer, Recurrent Ovarian Cancer
- Interventions
- Durvalumab, Eribulin
- Drug
- Lead sponsor
- Amy Tiersten
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST), Ovarian Cancer
- Interventions
- PLX3397, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 7 more
- Conditions
- Pancreatic Cancer, Renal Cell Cancer, Breast Cancer, Melanoma, Ovarian Cancer
- Interventions
- Cyclophosphamide, Fludarabine, Aldesleukin, Anti-hCD70 CAR transduced PBL
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Ovarian Neoplasms, Fallopian Tube Neoplasms, Primary Peritoneal Neoplasms
- Interventions
- Pegylated L-Asparaginase
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Ovarian Carcinoma
- Interventions
- NanoPac® 100 mg/m2, NanoPac® 200 mg/m2, NanoPac® 300 mg/m2, NanoPac® 400 mg/m2, Standard of Care Intravenous Chemotherapy
- Drug
- Lead sponsor
- NanOlogy, LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Minneapolis, Minnesota + 4 more
- Conditions
- Ovarian Cancer
- Interventions
- Panzem Nanocrystal Colloidal Dispersion (NCD)
- Drug
- Lead sponsor
- CASI pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Ovarian Choriocarcinoma, Ovarian Embryonal Carcinoma, Ovarian Mixed Germ Cell Tumor, Ovarian Teratoma, Ovarian Yolk Sac Tumor, Testicular Choriocarcinoma, Testicular Embryonal Carcinoma, Testicular Seminoma, Testicular Teratoma, Testicular Yolk Sac Tumor
- Interventions
- Laboratory Biomarker Analysis, Questionnaire Administration
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 19 Years
- Enrollment
- 932 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Renal Cell Carcinoma, Colorectal Adenocarcinoma, Non-squamous Non-small Cell Lung Cancer, Platinum-refractory Ovarian Carcinoma, Cervical Carcinoma
- Interventions
- Nintedanib, Bevacizumab
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Breast Cancer, Ovarian Cancer
- Interventions
- Genetic Counseling, Informed Consent Counseling
- Procedure
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2005
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Colorectal Cancer, Gastric Cancers, Ovarian Cancers, Pancreatic Ductal Adenocarcinoma
- Interventions
- GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT)
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
- Conditions
- Cervical Cancer, Ovarian Cancer
- Interventions
- etoposide
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1993
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 38 more
- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma, Thromboembolism, Vaginal Cancer, Vulvar Cancer
- Interventions
- fondaparinux sodium
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Upland, Pennsylvania
- Conditions
- Malignant Epithelial Mesothelioma, Adenocarcinoma of the Pancreas, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma of the Ovaries
- Interventions
- CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin
- Biological
- Lead sponsor
- Anza Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Bethesda, Maryland • Philadelphia, Pennsylvania
- Conditions
- Malignant Neoplasms of Female Genital Organs
- Interventions
- Fulvestrant, Abemaciclib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms
- Interventions
- disitamab vedotin
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 75
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 36 more
- Conditions
- Fallopian Tube Cancer, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
- Interventions
- cyclophosphamide, celecoxib
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2019
- U.S. locations
- 2
- States / cities
- Duarte, California • Pasadena, California
- Conditions
- Advanced Malignancies
- Interventions
- INCAGN01949, Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Incyte Biosciences International Sàrl
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more
- Conditions
- Ovarian Cancer
- Interventions
- 90Y-hu3S193, 111In-hu3S193
- Biological
- Lead sponsor
- Ludwig Institute for Cancer Research
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer, Colon Cancer, Pancreatic Cancer, Ovarian Cancer, Lung Cancer
- Interventions
- EXoPred
- Diagnostic Test
- Lead sponsor
- EXoPERT
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 1,400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 9
- States / cities
- Long Beach, California • Los Angeles, California • Honolulu, Hawaii + 6 more
- Conditions
- Solid Tumors
- Interventions
- Picoplatin
- Drug
- Lead sponsor
- Poniard Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 4 more
- Conditions
- Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
- Interventions
- PF-07209960
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 13
- States / cities
- Duarte, California • Los Angeles, California • Santa Monica, California + 3 more
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Interventions
- STRO-002
- Drug
- Lead sponsor
- Sutro Biopharma, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Los Angeles, California • San Francisco, California + 19 more
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma
- Interventions
- Collaborative Agenda-Setting Intervention
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts